Proteomics receives $2.16 million in R&D tax incentive
Filed with ASX · · 2 pages · English
Proteomics International Laboratories Ltd. on 6ix
Earlier from Proteomics International Laboratories
- AGM Chairman's Address and Investor Presentation
- September 2024 Quarterly Activities Report and Appendix 4C
- Esophageal cancer diagnostic delivers excellent results
- Update on commercialisation of PromarkerD in the USA
- Groundbreaking results for type 1 diabetes and kidney health
Later from Proteomics International Laboratories
- Breakthrough results for endometriosis diagnostic blood test
- Novel OxiDx test detects muscle damage in elite athletes
- December 2024 Quarterly Activities Report and Appendix 4C
- Interim Financial Report and Appendix 4D
- Proteomics opens CLIA certified reference laboratory in USA
Follow Proteomics International Laboratories into a list and get an email when it puts out news.
Follow Proteomics International Laboratories